These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

827 related articles for article (PubMed ID: 33781600)

  • 1. NIH funding for vaccine readiness before the COVID-19 pandemic.
    Kiszewski AE; Cleary EG; Jackson MJ; Ledley FD
    Vaccine; 2021 Apr; 39(17):2458-2466. PubMed ID: 33781600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Working Hard or Hardly Working? Regulatory Bottlenecks in Developing a COVID-19 Vaccine.
    Pregelj L; Hine DC; Oyola-Lozada MG; Munro TP
    Trends Biotechnol; 2020 Sep; 38(9):943-947. PubMed ID: 32600777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global health security as it pertains to Zika, Ebola, and COVID-19.
    Pannu J; Barry M
    Curr Opin Infect Dis; 2021 Oct; 34(5):401-408. PubMed ID: 34334661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Generalized Peptide Regions for Designing Vaccine Effective for All Significant Mutated Strains of SARS-CoV-2.
    Biswas S; Manna S; Dey T; Chatterjee S; Dey S
    Comb Chem High Throughput Screen; 2022; 25(3):414-428. PubMed ID: 34077341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanovaccines to combat virus-related diseases.
    Wu F; Qin M; Wang H; Sun X
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023 Mar; 15(2):e1857. PubMed ID: 36184873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zika Virus Vaccine Development.
    Morabito KM; Graham BS
    J Infect Dis; 2017 Dec; 216(suppl_10):S957-S963. PubMed ID: 29267918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Pandemic and Vaccines Update on Challenges and Resolutions.
    Khan WH; Hashmi Z; Goel A; Ahmad R; Gupta K; Khan N; Alam I; Ahmed F; Ansari MA
    Front Cell Infect Microbiol; 2021; 11():690621. PubMed ID: 34568087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Animal Research in Pandemic Responses.
    Brockhurst JK; Villano JS
    Comp Med; 2021 Oct; 71(5):359-368. PubMed ID: 34610857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outbreaks of publications about emerging infectious diseases: the case of SARS-CoV-2 and Zika virus.
    Ipekci AM; Buitrago-Garcia D; Meili KW; Krauer F; Prajapati N; Thapa S; Wildisen L; Araujo-Chaveron L; Baumann L; Shah S; Whiteley T; Solís-García G; Tsotra F; Zhelyazkov I; Imeri H; Low N; Counotte MJ
    BMC Med Res Methodol; 2021 Mar; 21(1):50. PubMed ID: 33706715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies.
    Beall RF; Moradpour J; Hollis A
    PLoS One; 2021; 16(10):e0258013. PubMed ID: 34679120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting COVID-19: A quick review of diagnoses, therapies, and vaccines.
    Shih HI; Wu CJ; Tu YF; Chi CY
    Biomed J; 2020 Aug; 43(4):341-354. PubMed ID: 32532623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mRNA Vaccine: How to Meet the Challenge of SARS-CoV-2.
    Jin Y; Hou C; Li Y; Zheng K; Wang C
    Front Immunol; 2021; 12():821538. PubMed ID: 35126377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future vaccines in pregnancy.
    Vress D
    Best Pract Res Clin Obstet Gynaecol; 2021 Oct; 76():96-106. PubMed ID: 33893037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 vaccine candidates in rapid development.
    Li L; Guo P; Zhang X; Yu Z; Zhang W; Sun H
    Hum Vaccin Immunother; 2021 Mar; 17(3):644-653. PubMed ID: 33121319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of a vaccinia virus-based severe acute respiratory syndrome coronavirus 2 vaccine candidate.
    Mei S; Fan Z; Liu X; Zhao F; Huang Y; Wei L; Hu Y; Xie Y; Wang L; Ai B; Liang C; Xu F; Guo F
    Front Immunol; 2022; 13():911164. PubMed ID: 35935962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies.
    Frederiksen LSF; Zhang Y; Foged C; Thakur A
    Front Immunol; 2020; 11():1817. PubMed ID: 32793245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.